Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
Background
Pallavi Prasad
On the right TRACK? Rivaroxaban to prevent ...

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Background
Cristina Adriana Popa
Heir to the Throne? Obinutuzumab in the ...

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?

finerenone

FIND CKD: The Visual Abstract

Is finerenone ready to move beyond diabetes?

The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.

The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.

Check out the newest VA created by our intern Raquel Barba

FIND CKD: El Resumen Visual

¿Está la finerenona lista para ir más allá de la diabetes?

El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC no diabética.

El siguiente reto ya no es si la finerenona tiene un lugar en la ERC no diabética, sino cómo combinarla de la mejor manera con el resto de los pilares del tratamiento para maximizar la protección renal.

No se pierdan el nuevo Visual Abstract creado por nuestra interna Raquel Barba

Análisis del Estudio FINE-HEART_El Resumen Visual

El análisis FINE-HEART llega a NephJC, donde se agrupan tres ensayos clínicos clave que evalúan el impacto de la finerenona en pacientes con insuficiencia cardíaca y enfermedad renal diabética.

¿Será la finerenona la próxima terapia de impacto para mejorar el eje cardio-reno-metabólico?

Descubre más en este resumen visual creado por la estudiante del NSMC, @KajareeG

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?